Maze Therapeutics R&D President Sells $736K in Stock After Option Exercise
Maze Therapeutics President of R&D and CMO Harold Bernstein sold 15,000 shares on March 20, 2026, in transactions totaling $736,439 after exercising options to acquire 15,000 shares at $10.42. The company has drawn positive analyst attention even as its shares trade well above fair value estimates and prepare to report earnings on April 6, 2026.